Covid-19 has exposed the underbelly of Bangladesh's inadequately equipped healthcare system, especially during the grimmer second wave. Timely nationwide inoculation could have brought some respite from the disease but, for Bangladesh, immunisation comes with its own set of logistical challenges. Three months into the nationwide inoculation programme, the country is facing an acute shortage of the Oxford-AstraZeneca vaccine produced by Serum Institute of India (SII).